People with HCV Archives – Page 2 of 4

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available

August 1, 2022
Dorrit Walsh

Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.

LAT CAB Video Presentation

July 28, 2022
Dorrit Walsh

This video, offered here in English, French, and Spanish, was made to be shown at the AfroCAB booth at the 24th International AIDS Conference.

Joint Statement from Leading HIV/AIDS and Viral Hepatitis Advocates regarding Manufacturer Action on the 340B Drug Pricing Program

April 20, 2022
Dorrit Walsh

A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program:

2021 TAG Update

December 16, 2021
Dorrit Walsh

As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

November 4, 2021
Dorrit Walsh

This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.

A Partnership to Expand Access to Lifesaving Testing and Treatment for Hepatitis C

September 20, 2021
Dorrit Walsh

Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.

Cover of the brief: Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

February 1, 2021
Dorrit Walsh

This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

New York Increases Access to Hepatitis C Treatment for Medicaid Patients

September 21, 2020
Dorrit Walsh

The National Viral Hepatitis Roundtable (NVHR), the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI), and the Treatment Action Group (TAG) today applauded New York State (NYS) Medicaid for removing the requirement that new patients receive prior authorization approval for hepatitis C treatment.

Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)

April 3, 2020
Dorrit Walsh

On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.

African Declaration to Eliminate Hepatitis C and Improve the Health of People Who Use Drugs

February 20, 2020
Dorrit Walsh

A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.